%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2018-01-15T20:26:34+05:30
2018-01-15T20:26:35+05:30
2018-01-15T20:26:35+05:30
Adobe InDesign CS6 (Macintosh)
uuid:9b023bfa-a7d2-3141-8520-2f0815e7667b
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.id:3231E86B262068118083B4CAD1F9ECF6
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2018-01-15T20:26:34+05:30
xmp.iid:093BACFB252068118083B4CAD1F9ECF6
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.did:01801174072068118DBB881A9EDFAAFA
default
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
8 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/Properties<>/Shading<>/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
121 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
11 0 0 11 45 51.6404 Tm
(28)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
BT
/T1_0 1 Tf
10 0 0 10 45 698.16 Tm
(18.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.008 Tw 0.58 0 Td
[(Angeli )0.6(P)159.9(, )0.5(Gin\350s )0.6(P)159.9(, )30.4(W)99.8(ong )0.6(F)129.9(, )0.5(et )0.6(al.)]TJ
/Span<>> BDC
( )Tj
EMC
12.963 0 Td
[(Diagnosis )0.6(and )0.6(management )]TJ
0.166 Tw -12.963 -1.2 Td
[(of acute kidne)14.9(y injur)-19.8(y in patients with cir)-29.8(rhosis: Re)24.9(vised )]TJ
0.136 Tw 0 -1.2 TD
[(Consensus Recommendations of the Inter)-19.7(national Club of )]TJ
0 Tw T*
(Ascites.)Tj
/Span<>> BDC
( )Tj
EMC
(J Hepatol)Tj
/Span<>> BDC
( )Tj
EMC
(2015;62:986\22674.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(19.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.012 Tw 0.58 0 Td
[(Garzia P)159.9(, F)49.8(er)-29.7(ri GM, Ilardi M, et al. P)14.9(athoph)29.8(ysiolo)24.9(gy)85(, clinical )]TJ
0.135 Tw T*
(features and management of hepatorenal syndrome. Euro)Tj
0 Tw (-)Tj
0.251 Tw T*
[(pean Re)24.9(vie)24.9(w for Medical and Phar)-19.7(macolo)24.9(gical Sciences )]TJ
0 Tw T*
(1998;2:181\226184. )Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(20.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.155 Tw 0.58 0 Td
[(Baraldi O)39.8(, )49.4(V)110.9(alentini C, Donati G, et al. Hepatorenal syn)]TJ
0 Tw (-)Tj
0.09 Tw T*
(drome: Update on diagnosis and treatment.)Tj
/Span<>> BDC
( )Tj
EMC
17.978 0 Td
[(W)99.9(orld J Neph)]TJ
0 Tw (-)Tj
-17.978 -1.2 Td
[(rolo)24.9(gy 2015;4\(5\):511\226520. )]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(21.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.057 Tw 0.58 0 Td
[(Care)14.9(g)4.9(aro L, Menon F)129.9(, )55(Angeli P)159.9(, et al. Limitations of ser)-19.7(um )]TJ
-0.035 Tw T*
[(creatinine )0.5(le)24.9(v)14.9(el )0.5(and creatinine )0.5(clearance )0.5(as )0.5(\036ltration mark)9.8(ers )]TJ
0 Tw T*
[(in cir)-29.8(rhosis. )55(Arch Inter)-19.7(n Med 1994 Jan 24;154\(2\):201\2265.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(22.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.149 Tw 0.58 0 Td
[(F)49.8(er)-19.8(nandez J)59.8(, Na)34.9(v)24.9(asa M, Garcia-P)14.9(ag)4.9(an JC, et al. Ef)24.9(fect of )]TJ
0.082 Tw T*
[(intra)34.9(v)14.9(enous alb)-4.8(umin on systemic and hepatic hemodynam)]TJ
0 Tw (-)Tj
0.082 Tw T*
[(ics and v)24.9(asoacti)25(v)14.9(e neurohor)-19.7(monal systems in patients with )]TJ
0.222 Tw T*
[(cir)-29.8(rhosis and spontaneous bacterial peritonitis. J Hepatol )]TJ
0 Tw T*
(2004;41\(3\):384\226390.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(23.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.022 Tw 0.58 0 Td
[(Sor)-19.8(t P)159.9(, Na)35(v)24.9(asa M, )55.3(Ar)-29.7(ro)44.9(y)19.8(o )50.2(V)199.9(, et al. Ef)25(fect of intra)34.9(v)14.9(enous alb)-4.8(u)]TJ
0 Tw (-)Tj
0.044 Tw T*
[(min on renal impair)-19.8(ment and mor)-19.8(tality in patients with cir)]TJ
0 Tw 23.667 0 Td
(-)Tj
-0.021 Tw -23.667 -1.2 Td
[(rhosis )0.5(and )0.6(spontaneous )0.5(bacterial )0.5(peritonitis. )50.3(The )0.6(Ne)24.9(w )0.5(Engl )0.5(J )]TJ
0 Tw T*
(Med 1999;341\(6\):403\226409.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(24.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.121 Tw 0.58 0 Td
[(Saler)-19.7(no F)129.9(, Gerbes )54.9(A, Gines P)160(, et al. Diagnosis, pre)24.9(v)14.9(ention )]TJ
0.227 Tw T*
[(and )0.5(treatment )0.6(of )0.5(hepatorenal )0.6(syndrome )0.5(in )0.6(cir)-29.8(rhosis. )0.5(Gut )]TJ
0 Tw T*
(2007;56\(9\):1310\2261318.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(25.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.104 Tw 0.58 0 Td
[(Lenz )0.5(K, )0.6(Buder )0.5(R, )0.5(Kapun )0.5(L, )0.6(et )0.5(al. )50.3(T)34.9(reatment )0.6(and )0.5(manage)]TJ
0 Tw (-)Tj
0.02 Tw T*
[(ment of ascites and hepatorenal syndrome: an update. )50(Ther)]TJ
0 Tw 23.667 0 Td
(-)Tj
-23.667 -1.2 Td
[(apeutic adv)25(ances in g)4.9(astroenterolo)25(gy 2015;8\(2\):83\226100.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(26.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.042 Tw 0.58 0 Td
[(Garcia-Tsao G, P)14.9(arikh CR, )49.6(V)39.8(iola )54.8(A. )54.7(Acute kidne)14.9(y injur)-19.7(y in )]TJ
0 Tw T*
[(cir)-29.8(rhosis. Hepatolo)25(gy 2008;48\(6\):2064\2262077.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(27.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.192 Tw 0.58 0 Td
[(Appenrodt B)29.7(, Zielinski J)59.8(, Brensing KA, et al. De)14.9(g)-19.7(ree of )]TJ
0.021 Tw T*
[(hepatic dysfunction and impro)45(v)14.9(ement of renal function pre)]TJ
0 Tw (-)Tj
-0.07 Tw T*
[(dict )0.5(sur)-19.8(vi)24.9(v)24.9(al )0.5(in )0.5(patients )0.5(with )0.5(HRS )0.6(type I: )0.5(a )0.5(retrospecti)25(v)14.9(e )0.5(anal)]TJ
0 Tw (-)Tj
T*
(ysis. Eur J Gastroenterol Hepatol 2009;21\(12\):1428\2261432.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(28.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.102 Tw 0.58 0 Td
[(P)14.9(ant C, Jani BS, Desai M, et al. Hepatorenal syndrome in )]TJ
0.002 Tw T*
[(hospitalized patients with chronic li)24.9(v)14.9(er disease: results from )]TJ
-0.025 Tw T*
[(the Nationwide Inpatient Sample 2002\2262012. J In)39.8(v)14.9(estig)4.9(ati)24.9(v)14.9(e )]TJ
0 Tw T*
(Medicine 2016;64\(1\):33\22638.)Tj
/T1_0 1 Tf
-0.025 Tc 0.025 Tw -1.8 -1.2 Td
(29.)Tj
/Span<>> BDC
1.145 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.022 Tw 0.655 0 Td
[(Alessandria C, Ozdo)24.9(g)4.9(an O)39.8(, Gue)25(v)24.9(ara M, et al. MELD score and)-25( )]TJ
-0.125 Tw T*
[(clinical type predict pro)24.9(gnosis in )0.5(hepatorenal )0.5(syndrome: )0.5(rele)24.9(v)24.9(ance)-25( )]TJ
0 Tw T*
[(to li)24.9(v)14.9(er transplantation. Hepatolo)24.9(gy 2005;41\(6\):1282\2261289.)]TJ
/T1_0 1 Tf
0 Tc -1.8 -1.2 Td
(30.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.182 Tw 0.58 0 Td
[(P)39.8(ericleous M, Sar)-19.8(no)39.8(wski )54.8(A, Moore )54.8(A, et al. )49.7(The clinical )]TJ
0.257 Tw T*
[(management )0.6(of )0.6(abdominal )0.5(ascites, )0.7(spontaneous )0.6(bacterial )]TJ
0.151 Tw T*
[(peritonitis )0.6(and )0.5(hepatorenal )0.6(syndrome: )0.6(a )0.5(re)24.9(vie)25(w )0.5(of )0.6(cur)-29.8(rent )]TJ
-0.022 Tw T*
(guidelines and recommendations. Eur J Gastroenterol Hepa)Tj
0 Tw (-)Tj
T*
(tol. 2016;28\(3\):e10\22618.)Tj
/T1_0 1 Tf
-0.015 Tc 0.015 Tw -1.8 -1.2 Td
(31.)Tj
/Span<>> BDC
1.175 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.014 Tw 0.625 0 Td
[(Hadengue )54.9(A, Gadano )54.9(A, Richard M, et al. Bene\036cial ef)24.9(fects of)-14.9( )]TJ
-0.084 Tw T*
[(the 2-da)35(y administration of terlipressin in patients with cir)-29.8(rhosis)-15( )]TJ
-0.04 Tw T*
[(and hepatorenal syndrome. J Hepatolo)24.9(gy 1998;29\(4\):565\226570.)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 26.4 58.8 Td
(32.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.026 Tw 0.58 0 Td
[(Uriz )0.5(J)59.8(, Gin\350s )0.5(P)159.9(, C\341rdenas )55.5(A, et )0.5(al. )50.2(T)99.8(erlipressin )0.5(plus )0.5(alb)-4.9(umin )]TJ
0.103 Tw T*
[(infusion: an ef)24.9(fecti)24.9(v)14.9(e and safe therap)29.8(y of hepatorenal syn)]TJ
0 Tw (-)Tj
T*
[(drome. J Hepatolo)25(gy 2000;33\(1\):43\22648.)]TJ
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -1.8 -1.2 Td
(33.)Tj
/Span<>> BDC
1.19 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.024 Tw 0.61 0 Td
[(Moreau R, Durand F)129.9(, P)39.8(o)45(ynard )50(T)99.9(, et al. )50(T)99.9(erlipressin in patients)-9.9( )]TJ
-0.122 Tw T*
[(with cir)-29.8(rhosis and type 1 hepatorenal syndrome: )55(A retrospecti)24.9(v)14.9(e)-10( )]TJ
0 Tw T*
[(multicenter study)85(. Gastroenterolo)24.9(gy 2002;122\(4\):923\226930.)]TJ
/T1_0 1 Tf
0 Tc -1.8 -1.2 Td
(34.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.075 Tw 0.58 0 Td
[(Mar)-19.8(t\355n\226Llah\355 )0.5(M, P\351pin MN)24.9(, Gue)24.9(v)24.9(ara M, et al. )50.3(T)99.8(erlipressin )]TJ
0.005 Tw T*
[(and alb)-4.8(umin vs alb)-4.9(umin in patients with cir)-29.8(rhosis and hepa)]TJ
0 Tw (-)Tj
0.267 Tw T*
[(torenal syndrome: a randomized study)84.9(. Gastroenterolo)25(gy )]TJ
0 Tw T*
(2008;134\(5\):1352\2261359.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(35.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.249 Tw 0.58 0 Td
[(Ar)-29.8(ro)45(y)19.7(o )49.4(V)200(, F)49.8(er)-19.7(nandez J)59.8(, Gines P)160(. P)14.9(atho)24.9(genesis and treat)]TJ
0 Tw (-)Tj
0.161 Tw T*
[(ment of hepatorenal syndrome. Seminars in li)24.9(v)14.9(er disease. )]TJ
0 Tw T*
(2008;28\(1\):81\22695.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(36.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.204 Tw 0.58 0 Td
[(Ghosh S, Choudhar)-19.8(y NS, Shar)-19.8(ma )55.1(AK, et al. Noradrena)]TJ
0 Tw (-)Tj
0.158 Tw T*
(line vs terlipressin in the treatment of type 2 hepatorenal )Tj
0.282 Tw T*
[(syndrome: a randomized pilot study)85(. Li)25(v)14.8(er Inter)-19.7(national )]TJ
0 Tw T*
(2013;33\(8\):1187\2261193.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(37.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.036 Tw 0.58 0 Td
[(Singh )49.5(V)200(, Ghosh S, Singh B)29.8(, et al. Noradrenaline vs. terlipres)]TJ
0 Tw (-)Tj
-0.006 Tw T*
[(sin )0.5(in )0.5(the )0.5(treatment )0.5(of )0.5(hepatorenal )0.5(syndrome: )55.5(A )0.5(randomized )]TJ
0 Tw T*
[(study)85(. J Hepatolo)24.9(gy 2012;56\(6\):1293\2261298.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(38.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.156 Tw 0.58 0 Td
[(Ca)34.9(v)24.9(allin M, Kamath PS, Merli M, et al. )49.7(T)99.9(erlipressin plus )]TJ
0.164 Tw T*
[(alb)-4.9(umin v)14.9(ersus midodrine and )0.5(octreotide plus alb)-4.9(umin in )]TJ
0.04 Tw T*
[(the treatment of hepatorenal syndrome: )54.6(A randomized trial. )]TJ
0 Tw T*
[(Hepatolo)25(gy 2015;62\(2\):567\226574.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
[(39.)29.8( )]TJ
/Span<>> BDC
( )Tj
EMC
/T1_1 1 Tf
0.084 Tw 1.8 0 Td
[(Gluud )0.5(LL, )0.5(Christensen )0.5(K, )0.5(Christensen )0.5(E, )0.5(et )0.5(al. )0.5(Systematic )]TJ
0.219 Tw T*
[(re)24.9(vie)24.9(w of randomized trials on v)24.9(asoconstrictor dr)-19.8(ugs for )]TJ
0 Tw T*
(hepatorenal syndrome.)Tj
/Span<>> BDC
( )Tj
EMC
[(Hepatolo)25.1(gy 2010 F)49.7(eb;51\(2\):576\22684.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(40.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.02 Tw 0.58 0 Td
[(La)34.9(v)24.9(a)35(yssiere L, Kallab S, Cardeau-Desangles )0.6(I, et al. Impact )]TJ
0.027 Tw T*
[(of molecular adsorbent recirculating system on renal reco)45(v)]TJ
0 Tw (-)Tj
0.161 Tw T*
[(er)-19.7(y )0.5(in type-1 )0.6(hepatorenal )0.5(syndrome )0.6(patients )0.5(with )0.5(chronic )]TJ
-0.077 Tw T*
[(li)24.9(v)14.9(er f)-9.8(ailure. J Gastroenterol Hepatol 2013;28\(6\):1019\2261024.)]TJ
/T1_0 1 Tf
0 Tw -1.8 -1.2 Td
(41.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.08 Tw 0.58 0 Td
[(W)99.9(ong F)129.9(, P)14.9(antea L, Snider)-19.8(man K. Midodrine, octreotide, alb)-4.8(u)]TJ
0 Tw (-)Tj
0.022 Tw T*
[(min, and )50.2(TIPS in selected patients with cir)-29.8(rhosis and type 1 )]TJ
0 Tw T*
[(hepatorenal syndrome. Hepatolo)25.1(gy 2004;40\(1\):55\22664.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(42.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.17 Tw 0.58 0 Td
[(Brensing KA, )50.2(T)99.8(e)14.9(xtor J)59.8(, P)39.8(erz J)59.8(, et al. Long ter)-19.8(m outcome )]TJ
0.413 Tw T*
[(after transjugular intrahepatic )0.5(por)-19.8(tosystemic stent-shunt )]TJ
0.172 Tw T*
[(in non-transplant cir)-29.8(rhotics )0.5(with hepatorenal )0.5(syndrome: )0.5(a )]TJ
0 Tw T*
[(phase II study)85(. Gut 2000;47\(2\):288\226295.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(43.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.363 Tw 0.58 0 Td
[(Siramolpiw)24.9(at S. )49.5(T)35(ransjugular intrahepatic por)-19.8(tosystemic )]TJ
-0.02 Tw T*
[(shunts and por)-19.8(tal h)29.8(yper)-19.8(tension-related complications. )29.6(W)99.9(orld )]TJ
0 Tw T*
(J Gastroenterol 2014;20\(45\):16996\22617010.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(44.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.432 Tw 0.58 0 Td
[(W)99.9(ong )0.5(F)129.9(, Leung )30.4(W)149.9(, )55.4(Al )0.5(Beshir )0.6(M,et )0.5(al. )0.5(Outcomes )0.6(of )]TJ
0.23 Tw T*
[(patients with cir)-29.8(rhosis and hepatorenal syndrome type 1 )]TJ
0.339 Tw T*
[(treated with li)24.9(v)14.9(er transplantation. Li)24.9(v)14.9(er )49.7(T)35(ransplantation. )]TJ
0 Tw T*
(2015;21\(3\):300\226307.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(45.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.183 Tw 0.58 0 Td
[(Goldaracena N)24.9(, Mar)15(quez M, Selzner N)24.9(, et al. Li)24.9(ving vs. )]TJ
0.205 Tw T*
[(deceased donor li)24.9(v)14.9(er transplantation pro)44.9(vides comparab)19.8(le )]TJ
0.04 Tw T*
[(reco)45(v)14.9(er)-19.8(y of renal function in patients with hepatorenal syn)]TJ
0 Tw (-)Tj
-0.023 Tw T*
[(drome: a matched case-control study)85(. )54.5(American J )49.4(T)34.9(ransplan)]TJ
0 Tw (-)Tj
T*
(tation 2014;14\(12\):2788\2262795.)Tj
ET
endstream
endobj
72 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 281.5651 54.1778 Tm
(The Southwest Respiratory and Critical Care Chronicles 2018;6\(22\):21\226\
28)Tj
ET
endstream
endobj
73 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 45 68.8957 cm
0 0 m
540 0 l
S
Q
10 M
q 1 0 0 1 45 740.2762 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 45 751.5262 Tm
(Shredi et al.)Tj
/Span<>> BDC
( )Tj
EMC
57.216 0 Td
(Hepatorenal Syndrome)Tj
ET
endstream
endobj
123 0 obj
<>
endobj
124 0 obj
<>
endobj
125 0 obj
<>stream
H\j0~
CI
&0r t1NzOJ3o}%U}]?CF]lipKT|W eq]7*! 4xƕJނл<|U
f@YŎ>zik; $Q-yYxO%3Z|k0JohOJΝn?lۧd=F&tF&C2w̢Y̕p|>0Kܜ'aJ^[p,q[d[U\6M=5q}~@*W /9
endstream
endobj
126 0 obj
<>stream
HlU TUGYPDTנA
apAeQD0hԨ:hpc3F".qC.#,K2M99INu[hŐ`lgkd^VP@Lmqx*bR#[<TtD3#oLܞ?hߛ\y6:6)>2$Ҙx4;dž$ȡ@g|!<